June 24 (Reuters) - The U.S. Food and Drug
Administration said on Tuesday that it is investigating reports
of two deaths due to acute liver failure in non-ambulatory
Duchenne muscular dystrophy patients after receiving Sarepta
Therapeutics' ( SRPT ) gene therapy, Elevidys.